UAE’s state-owned holding company Mubadala Investment Company (Mubadala) has invested $250 million in US-based biosimulation software company Certara as part of its plan to extend its healthcare and life sciences investment portfolio.
According to the statement, the investment is in line with Mubadala’s strategy of enabling innovation to address unmet clinical needs and drive cost efficiencies.
Mubadala and some existing institutional Certara shareholders, including a shareholder affiliated with EQT, have entered into an agreement under which an affiliate of Mubadala will purchase an aggregate of 9,615,384 shares at $26 per share from the shareholders in a private transaction.
The acquisition is expected to be completed on August 2, 2021. After the transaction, EQT will remain a significant shareholder in the company.
“We are pleased to welcome a significant new investment from Mubadala, a sovereign investor with deep expertise in life sciences that is focused on creating lasting value. As a newly listed public company, we are excited by Mubadala’s recognition of Certara’s performance and position as a global leader in biosimulation, especially as we execute on our next phase of growth.”
Mr. Eric Liu, Co-Head of EQT’s Global Healthcare Sector Team noted, “We welcome Mubadala as a new shareholder of Certara. EQT remains a significant investor in Certara, and we look forward to continuing to support the management team in their efforts to accelerate medicines to patients through the use of biosimulation.”
“Biosimulation is transforming traditional drug development via computational approaches that save time and cost throughout the entire biopharma R&D process. We are proud to have invested in Certara, whose industry-standard software is accelerating the development of new medicines that improve the lives of patients,” commented Ms. Camilla Languille, Head of Life Sciences at Mubadala.